Ironwood signs up with the leading prescription app developer, but Pear is not to everyone’s taste.
Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.
In buying a company previously thought of as a competitor GTX hopes to dominate the spinal cord injury space.
A product sale nets the Australian company some much-needed cash, but its plan for the future is highly questionable.
The group has the only approved cell-based cancer blood test in the world, but competing in an increasingly cutthroat market will be tough.
A shift to higher-growth systems and a tie-up with Illumina are sensible moves, but will take time to pay off.
Portico hits noninferiority, but safety looks doubtful. Abbott might want to prioritise a different approach.
Data on the company’s pacemaker-neurostimulator combo are probably good enough to permit further development – but first the company wants to hook a partner.